SHL:ASXSonic Healthcare Limited Analysis

Sonic Healthcare is trading at AUD 21.20, just above the calculated support level of 20.95 and below its 30‑day DCF fair value of 21.80, suggesting a modest upside. The 20‑day SMA (22.58) sits marginally under the 50‑day SMA (22.60) and both are well under the 200‑day SMA (23.78), reinforcing a bearish medium‑term trend. Momentum indicators are weak – RSI is at 34.9 (near oversold) and the MACD histogram is negative, while volume has been decreasing, indicating limited buying pressure. Fundamentally, the company posted 16.6% revenue growth, a solid gross margin of 32.8% and a modest operating margin of 9%, with free cash flow comfortably positive.
The dividend yield of 5.09% is attractive, but a payout ratio of roughly 97% raises questions about sustainability. Valuation metrics (PE 19.1 vs industry 26.2, PB 1.22) point to the stock being undervalued relative to peers. Low beta (≈0.22) suggests limited market‑wide volatility, yet the 30‑day realized volatility of ~36% and a recent max drawdown of 28% highlight price risk. Geographic exposure across Australia, the United States and Germany adds diversification but also introduces regulatory and currency considerations. Overall, the stock presents a blend of value and growth characteristics, with the dividend offering income but requiring careful monitoring.